Press-release for stocks publishing date 2021 - 10

Prices are updated after-hours

Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
Published: 2021-10-14 (Crawled : 21:00) - globenewswire.com
VRTX | News | $394.43 0.24% 0.24% 1.3M

| 117.13% | O: 0.32% H: 0.37% C: -0.39%
SGEN | $228.74 0.1% 20M

| 34.4% | O: 0.24% H: 2.56% C: 1.25%
SNY | News | $46.32 2.05% 2.01% 3.3M

| -6.34% | O: -0.35% H: 1.12% C: 0.89%
NRIX | $13.6 -5.82% -6.18% 1M

| -49.33% | O: 0.91% H: 1.23% C: 0.24%
financial results results

Insights from the world's leading KOLs on the prospects of launched and pipeline therapies for non-small cell lung cancer
Published: 2021-10-14 (Crawled : 18:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

| -5.62% | O: 1.2% H: 0.08% C: -0.43%
lung cancer cancer therapy

Tentarix Biotherapeutics Emerges with $50 Million Series A
Published: 2021-10-14 (Crawled : 14:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

| -5.62% | O: 1.2% H: 0.08% C: -0.43%
FATE | $4.795 -4.86% -5.11% 2.7M

| -91.06% | O: 1.41% H: 3.89% C: 2.48%
iot merge

| -5.62% | O: 1.2% H: 0.08% C: -0.43%
AGTC | $0.3936 1.23% 0.0%

| -85.64% | O: 0.36% H: 2.55% C: -0.73%

MAIA Biotechnology, Inc. Announces $6.2 Million Financing to Advance Targeted Immuno-Oncology Studies
Published: 2021-10-14 (Crawled : 13:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

| -5.62% | O: 1.2% H: 0.08% C: -0.43%
biotech technology iot

FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19
Published: 2021-10-14 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M

| -5.62% | O: 1.2% H: 0.08% C: -0.43%
REGN | $896.27 0.26% 0.25% 500K

| 64.72% | O: 1.07% H: 2.19% C: 0.47%
covid treatment fda casirivimab fda acceptance

CRISPR Therapeutics Announces Transition of Chief Financial Officer
Published: 2021-10-14 (Crawled : 12:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M